INTRODUCTION
Since the discovery of Epstein-Barr virus (EBV) in 1964, EBV has been etiologically implicated in an increasing number of human diseases (20) . Although primary infection with EBV during childhood is usually asymptomatic, nearly one-half to two-thirds of primary infections with this virus in older adolescents and young adults result in overt clinical disease such as infectious mononucleosis (IM) (20) . EBV has also been implicated as a cause of endemic Burkitt's lymphoma and undifferentiated nasopharyngeal carcinoma because the virus genome is present in the tumors and because high levels of EBV antibody titers are found in the serum of patients with these afflictions (20) . Additionally, various EBV-carrying lymphoproliferative disorders have been increasingly reported in patients with inherited or acquired immunodeficiencies (20) . Recently, another category of EBV-related disease, "chronic EBV infections" or "chronic mononucleosis," has been described in persons without a clearly defined underlying disease (3, 4, 10, 26, 28, 29) . There is, however, considerable debate about this disease or syndrome because of a failure to establish definitive diagnostic criteria. Nevertheless, rare patients with this syndrome have developed severe symptoms obviously associated with an active EBV infection (7, 9, 11-15, 18, 19, 21, 22, 24, 31) . Therefore, we propose that this disorder be designated severe chronic active EBV infection syndrome (SCAEBV).
Patients with SCAEBV, usually children and young adults, often develop life-threatening complications over the course of months to several years. The patients show extremely high immunoglobulin G (IgG) antibody titers to Epstein-Barr viral capsid antigen (VCA) and early antigen (EA). Extensive lymphadenopathy, hepatosplenomegaly, a tendency for pancytopenia, and polyclonal gammopathy are commonly found. Although histopathological findings for affected tissues are generally benign, some patients have * Corresponding author.
developed B-cell or T-cell lymphoproliferative diseases (7, 11, 14, 21) .
We have reviewed the English-language literature for reports of chronic active EBV infection (CAEBV) by a computer search via MEDLINE for the years 1978 to 1990, by examining Index Medicus for the years 1978 to 1990, and by examining major textbooks regarding infectious diseases, virology, herpesviruses, immunodeficiency, and EBV. Indexing terms included EBV, chronic, active, and IM. We then selected the reported cases using our proposed criteria of a case definition for SCAEBV ( Table 1 ). The criteria were based on the clinical, pathological, and virological findings for this syndrome. Here we review the historical, clinical, virological, pathological, and immunological aspects of this syndrome. Additionally, this review includes 10 patients (8 from Japan and 2 from the United States) with SCAEBV whom we have recently studied at the Hokkaido University School of Medicine, Sapporo, Japan, and the University of Nebraska Medical Center, Omaha. Further description of these patients may lead to a better understanding of this enigmatic syndrome.
HISTORICAL BACKGROUND In 1948, Isaacs described a prolonged clinical course of IM lasting from months to years (6) . During the late 1970s and early to middle 1980s, several groups described a protracted illness usually preceded by IM but with persistent fatigue, headaches, myalgia, lymphadenopathy, and intermittent or low-grade fever (3, 4, 10, 26, 29) . Unexpectedly, unusual profiles of antibodies to EBV were common in this syndrome. Specifically, the titers of EBV IgG antibodies to VCA and EA were substantially higher in patients than in controls. Because of these serologic patterns and clinical symptoms, it was proposed that the syndrome arose from a chronic EBV infection. In 1978, Virelizier et al. described a case of a severe type of CAEBV (31) . The affected girl had a chronic disease characterized by fever, lymphadenopathy, interstitial pneumonitis, thrombocytopenia, and polyclonal hypergammaglobulinemia. She had extremely high EBV (24, 31) . Other symptoms, such as debilitating fatigue, sore throat, lymph node tenderness and pain, headache, myalgia, and arthralgia, are also encountered in these patients. Besides polyclonal gammopathy, in four patients with SCAEBV whom we recently studied only the IgGl subclass was elevated (22) . Additionally, only one familial case of this syndrome has been reported (9) . The patient (father of the affected girl) described, however, did not (5, 17, 18, 20) . Additionally, the isolation of a defective nontransforming strain of EBV from a child with this syndrome suggests that the occurrence of EBV strains with a deleted transforming portion may explain the difficulty in establishing EBVpositive cell lines in certain patients (1, 2) . Furthermore, a recent report described a homogeneous episomal population of EBV in affected tissues, including peripheral blood mononuclear cells, lymph node, lung, aorta, and spleen, in patients with SCAEBV (13 (7, 9, 11-15, 18, 19, 21, 22, 24, 31) . Variable follicular lymphoid hyperplasia and atypical plasmacytosis are common findings in enlarged lymph nodes. Furthermore, no evidence of virus-associated hemophagocytic syndrome (23, 27) is observed in bone marrow specimens. However, over the course of the disease, some patients develop oligoclonal and/or monoclonal B-cell or T-cell lymphoproliferative diseases (7, 11, 14, 21 who have SCAEBV and who have developed T-cell lymphoproliferative diseases: (i) T-cell lymphoma with clonal rearrangement of the T-cell receptor gene in three patients (11) , (ii) clonal proliferation of T cells containing EBV DNA in one patient (7), and (iii) EBV-positive CD4 cells in the circulation of another patient (14) . Although an interpretation of these results is difficult, the malignant or circulating T cells seem to be EBV genome positive both in Southern blot analysis and in in situ hybridization. In contrast, we have demonstrated an oligoclonal rearrangement of the heavychain J-region fragment of the immunoglobulin of the infiltrated cells in the spleen of a patient with SCAEBV (21) . More studies are needed to establish whether the virus evokes T-cell as well as B-cell lymphomagenesis in patients with SCAEBV. No specific chromosomal abnormalities have been reported in patients with this syndrome (7, 9, 11-15, 18, 19, 21, 22, 24, 31) . A summary of the pathological findings is given in Table 4 .
IMMUNOLOGICAL STUDIES
Defenses against EBV infection include mucus, various interferons, natural killer (NK) cells, neutralizing antibodies, antibody-dependent cell-mediated cytotoxicity, and human leukocyte antigen-restricted or -nonrestricted EBV-specific cytotoxic T cells (20) . A lack of these immunological defenses often results in EBV-induced lymphoproliferation. For example, as in patients with either inherited or acquired immunodeficiency (20) , no consistent underlying immunological abnormalities have been found in patients with SCAEBV (7, 9, 11-15, 18, 19, 21, 22, 24, 31) . Rather, various heterogeneous immune defects, such as defective immune interferon secretion, low NK cell activity, low mitogen stimulation of peripheral blood lymphocytes, and an inverted or increased CD4/CD8 ratio, have been reported. Low NK cell and antibody-depen-9 dent cell-mediated cytotoxicity activities and inverted CD4/CD8 ratio 3 Circulating immune complexes and 15 inverted CD4/CD8 ratio 4 Circulating immune complexes and 15 no EBV cytotoxicity 5 Low mitogen stimulation response 15 6 Inverted CD4/CD8 ratio 24 7 Inverted CD4/CD8 ratio 24 13 Low NK cell activity 19a 15 Low NK cell activity 12 21 Low NK cell activity and increased 21, 22 CD4/CD8 ratio 22 Increased CD4/CD8 ratio 14 23 Increased CD4/CD8 ratio 7 26 Inverted CD4/CD8 ratio 22
a Unpublished data included.
Because of the difficulties in establishing EBV-positive cell lines, assessing EBV-specific cytotoxic T-cell activity is difficult. However, Kuis et al. reported that one patient exhibited normal cytotoxicity, whereas a second patient exhibited no EBV-specific cytotoxicity and unusually high levels of virus-infected B cells in the peripheral blood and the affected lymph node (15) . As mentioned earlier, some patients with SCAEBV fail to make antibodies to EBNA 1, suggesting some defect in the immunosurveillance of EBV infection, a cellular alteration, or a mutation elsewhere in the viral genome (5, 17, 18) . Joncas et al. reported a lack of EBV antibody-dependent cell-mediated cytotoxicity, neutralizing antibodies, and NK cell activity in a patient with this syndrome (8) . In contrast, we recently demonstrated the presence of normal neutralizing antibodies to EBV in four patients with SCAEBV (22) . Taken together, these data indicate that a subtle heterogeneous immunodeficiency may be an underlying component in patients with this syndrome. The immunological abnormalities seen in this syndrome are listed in Table 5 .
ETIOLOGY
The factors and mechanism(s) responsible for SCAEBV remain unclear. However, the magnitude of the EBV antibody response to the replicative antigens of EBV strongly indicates that unregulated replication of EBV is the main feature of the illness. Alfieri et al. isolated from the saliva of a child with SCAEBV a virus which induced EBV EA in Raji cells and in fresh EBV-negative peripheral blood lymphocytes (1, 2). The authors suggested that atypical EBV strains, such as a nontransforming lytic strain, may be the etiologic agents in certain patients. We have recently detected both adenovirus type 2 and EBV genomes in lesions in a patient with SCAEBV (21) . Additionally, using monoclonal antibodies to adenoviruses, we have demonstrated that the virus isolated from throat washings of the patient induced adenovirus-related antigen expression in Raji cells (21; unpublished data (22) . Two low-molecular-weight RNAs encoded by EBV and designated EBV-encoded RNA-1 and RNA-2 (EBER-1 and EBER-2, respectively) can functionally substitute for the adenovirus-associated RNA-1 and RNA-2 (VA-1 and VA-2) of adenovirus types 2 and 5, respectively, and are responsible for the lytic growth of the adenoviruses (21, 22) . When normal B lymphocytes are infected by EBV in vitro, the cells are immortalized into continuously dividing permanent cell lines (20) . On the other hand, infection of human cells by adenoviruses generally leads to a lytic event (21) . Thus, we have reasoned that despite the expression of an activated EBV infection in vivo, the difficulty in establishing EBV-positive cell lines may be related to EBV activation of adenovirus-induced cell lysis. Additionally, adenoviruses may enhance the expression of EBV-related lytic antigens such as EA and VCA (21) . Adenoviruses can reduce the expression of human histocompatibility class 1 antigens on infected cells (21, 22) , whereas EBV induces a transient immunosuppression (21, 22) in patients during acute infections. Therefore, the combination and/or interaction of these two lymphotropic viruses may be responsible for the development of SCAEBV in some patients. Further studies, however, are needed to confirm this possibility.
The pathogenetic mechanism(s) responsible for the development of oligoclonal and/or monoclonal B-cell or T-cell lymphoproliferative diseases remains unclear. It has been postulated that malignant transformation by EBV of proliferating T cells responding to EBV-infected cells results in the development of T-cell neoplasms (11) . Although the finding of monoclonality in lymphoproliferative diseases may represent extreme clonal expansion and does not necessarily indicate neoplastic transformation and although no consistent underlying immunological abnormalities have been found in patients with SCAEBV, it is well known that the transition from polyclonal to monoclonal EBV-induced lymphoproliferative lesions occurs in patients with immunodeficiencies (20) . This observation may explain the development of B-cell lymphoproliferative diseases in patients with SCAEBV. More cases, however, should be studied to evaluate B-cell or T-cell lymphoproliferative diseases in patients with SCAEBV.
THERAPY
No effective treatment is available for SCAEBV. Acyclovir, a potent antiherpesvirus agent which is useful for treating some transplant recipients with life-threatening EBV-induced polyclonal lymphoproliferative disease, has no significant clinical effect in patients with SCAEBV (15, 21, 22) . However, some success with recombinant interleukin-2 treatment has been reported (12) . One patient was in a clinical remission for more than 6 months as a result of the restoration of NK cell activity. Several promising new approaches for treating EBV-induced lymphoproliferative diseases, including high-dose intravenous immunoglobulin and alpha interferon, are under investigation (22; unpublished data). The results of these studies may provide new approaches for the assessment and treatment of SCAEBV.
DIFFERENTIAL DIAGNOSIS
Other clinical conditions that may produce symptoms similar to those of SCAEBV must be excluded by a thorough evaluation based on history, physical examination, and appropriate laboratory findings. For example, this syndrome has to be differentiated from EBV-induced lymphoproliferative disorders in patients who have increased EBV antibody titers and who may have inherited or acquired immunodeficiencies (20) . These diseases result from defective immune responses during the primary EBV infection or a reactivated EBV infection with acquired immunodeficiency. In these cases, however, the underlying immunodeficiency can be detected.
Rheumatic disease, such as systemic lupus erythematosus and rheumatoid arthritis (33) , and chronic inflammatory disease or lymphoid malignancy, such as angioimmunoblastic lymphadenopathy with dysproteinemia, leukemia, and Hodgkin's disease (16, 25, 32) , should be considered in the differential diagnosis. Patients with these diseases often have elevated antibody titers to EBV. However, they rarely exhibit IgG antibody titers to VCA as high as .5,120, as are seen in patients with SCAEBV. Moreover, clinical and histopathological features are distinctive in these other diseases.
CONCLUDING REMARKS
Although lymphoproliferation, such as IM arising from EBV infection, is almost always self-limiting, some patients develop uncontrolled proliferation resulting from various degrees of immunodeficiency, genetic background, or other unknown factors (20) . Since the discovery of EBV, this virus has been etiologically implicated in an increasing number of human diseases (20) . During the 1980s, several studies focused on patients with chronic fatigue and other nonspecific symptoms following acute IM without a clearly defined underlying disease (3, 4, 10, 26, 28, 29) . Defining the etiology of such syndromes is difficult because the interpretation of EBV serology is complex and the nonspecific symptoms are varied. Although we cannot completely rule out other diseases, the SCAEBV which we have described appears to be distinctive because of its characteristic clinical features. The case definition criteria in Table 1 should help to improve the comparability and the reproducibility of clinical research and epidemiologic studies for evaluating patients. This review is intended to provide further opportunities to investigate this enigmatic syndrome. The results of these investigations may lead to new approaches for the assessment and treatment of lymphoproliferative disorders of unknown etiology.
